Advitech Announces An Agreement With A Pharmaceutical Company For France And Belgium Concerning Its Psoriasis Product, Dermylex™
10 April 2007 14:29
Advitech announced today that they concluded an agreement in principle with Iprad Santé, a pharmaceutical corporation specialising in the development and commercialisation of dermatological and gynaecological products. This agreement targets the completion of a marketing and supply agreement for Dermylex™ in France, Belgium and, eventually, other European countries. This agreement has two short term objectives:
- The signature of a definitive marketing and supply agreement for exclusive sale of Dermylex in France and Belgium before April 30, 2007
- The possibility to include, before April 30, 2007, Germany, Switzerland and Spain to the existing statement of agreement and thereafter sign a definitive marketing and supply agreements for each of these countries
Commercialisation of Dermylex in France and Belgium is planned to start in the third quarter of 2007, and a pre-launch activity is scheduled from June 22nd to June 24th at the Second Congress on Psoriasis held in Paris. During this congress, Advitech will realise a scientific presentation of the Dermylex in one of the congress workshops. A training session for French and European dermatologists will also be presented. The first delivery of Dermylex to Iprad Santé is planned for June 2007 and others should follow in the following quarters.
Dermylex will be distributed in drugstores: there are more than 22,000 drugstores of these for France alone. "This agreement is important for Advitech on two points: it sets up a first commercial partnership with a pharmaceutical company with a focus on dermatology and it validates our technological platform and clinical program on Dermylex," commented Renaud Beauchesne, president and chief executive officer of Advitech.
Pierre-Marie Defrance, president and chairman of Iprad Holding, added: "Right now, there is a new interest from psoriasis patients for a product like Dermylex and, after the analysis by our experts of the scientific and technical files available on Dermylex, we are confident to position this product effectively on the French and European dermatologic markets. Iprad Santé employs 105 medical visitors and 32 sales representatives and our business plan is forecasting a rapid growth by leveraging our dermatological product portfolio".
Considering this new agreement, Advitech has given a notice to Cothera S.A of the termination to the 2005 agreement. Under this agreement, Cothera had the exclusive right to market Dermylex in France. Cothera has not reached the objectives defined by the contract and its cancellation has no legal impact.
For more information on this company:
Advitech - Natural Products for Psoriasis
Copyright 2007SPG Media Limited a subsidiary of SPG Media Group PLC
